Oxford Biomedica PLC (LON:OXB), a global quality and innovation-led cell and gene therapy CDMO, has announced the appointment of Dr Joachim Kreuzburg as an Independent Non-Executive Director, effective on 23 November 2026.
Dr Kreuzburg has more than 20 years of public company leadership experience in the global life sciences industry. He was Chair of the Executive Board and Chief Executive Officer of Sartorius AG (XETRA: SRT3) from 2003 to 2025. He was also Chair of the Board of Sartorius Stedim Biotech S.A. (Euronext Paris: DIM) from 2007 to 2025, and its Chief Executive Officer until 2023. Under his leadership, Sartorius transformed from a supplier of filtration devices and weighing instruments into a leading life sciences tools company and one of the foremost global players in its field. The transformation followed a clear strategic vision, driven by a focus on innovation and commercial excellence and included the acquisition of 24 complementary and differentiated businesses. During Dr Kreuzburg’s tenure, Sartorius AG’s stock market valuation rose from c. EUR 90 million to around EUR 14 billion.
Dr. Kreuzburg currently serves as a member of the Supervisory Board of Carl Zeiss AG, an optical technologies company, and as Deputy Chair of prosthetics company Ottobock SE (XETRA: OBCK). He is Chair of Cube Biotech GmbH and a member of the advisory group of Novo Holdings. Beyond his corporate roles, he is a member of the Board of Deutscher Stifterverband, which funds research and academia, a member of the Senate of the Max Planck Gesellschaft, and a member of the advisory board of the Berlin Institute of Health.
Relevant disclosures
Save as disclosed, there are no disclosures required to be made in accordance with UKLR 6.4.8(R).
Dr Roch Doliveux, Chair of OXB, commented: “OXB is at an important stage in its growth, with its multi-vector CDMO network now spanning the UK, France and the US, and a clear plan for the years ahead. Joachim’s track record of transforming and scaling a leading global biopharma research and manufacturing partner, delivering strong revenue and profit growth whilst executing and integrating acquisitions, will be invaluable as we execute on this strategy. I am delighted to welcome him to the Board.”
Dr Joachim Kreuzburg said: “Cell and gene therapies are among the most promising areas of modern medicine, and OXB has built a differentiated position as a global, innovation-led CDMO with deep viral vector expertise. Having spent my career scaling life science businesses and supporting biopharma customers through every stage of development, I see a significant opportunity ahead for OXB. I am personally excited to join the Board and to work with Roch, OXB’s CEO Frank Mathias and the team to help deliver the Company’s growth ambitions.”
